The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Cosmos Health Inc. (NASDAQ: COSM) has announced its plans to launch the Liv18 supplement in the United States during the second quarter of 2026. The product is powered by BergacynFF®, a patented botanical blend that has been clinically proven to reduce liver fat accumulation and support healthy body weight. This upcoming launch is a key component of the company's ongoing expansion strategy within the global healthcare and wellness sector. By introducing Liv18, Cosmos Health aims to leverage clinically proven ingredients to address growing consumer demand for liver health solutions. The move represents a significant step in strengthening the company's product portfolio and market presence in the competitive U.S. supplement industry. Investors are monitoring this development as a potential long-term catalyst for growth, pending the product's commercial success and market adoption.
Sign in to access this content
Sign In